Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 1.00 |
| ▸ | GSK3B | P49841 | 4/20 | 0.80 |
| ▸ | XDH | P47989 | 1/20 | 0.79 |
| ▸ | MMP13 | P45452 | 3/20 | 0.76 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.76 |
| ▸ | CRHBP | P24387 | 1/20 | 0.66 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.66 |
| ▸ | CNR1 | P21554 | 1/20 | 0.59 |
| ▸ | MMP3 | P08254 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | MGAM | O43451 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | SI | P14410 | 1/20 | 0.56 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.56 |
| ▸ | NAT1 | P18440 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17576954 | 0.90 | IDH1 (0.82) | IDH1GSK3BXDHMMP13ADAMTS5 | |
| SCHEMBL18504345 | 0.90 | IDH1 (0.81) | IDH1GSK3BXDHMMP13ADAMTS5 | |
| SCHEMBL18067420 | 0.86 | IDH1 (0.76) | IDH1GSK3BXDHMMP13ADAMTS5 | |
| SCHEMBL1249082 | 0.86 | ADAMTS5 (1.00) | IDH1GSK3BMMP13ADAMTS5CNR1 | |
| SCHEMBL12891797 | 0.86 | ADAMTS5 (1.00) | IDH1GSK3BMMP13ADAMTS5CNR1 | |
| SCHEMBL1249080 | 0.86 | ADAMTS5 (1.00) | IDH1GSK3BMMP13ADAMTS5CNR1 | |
| SCHEMBL20976492 | 0.83 | ADAMTS5 (0.74) | IDH1GSK3BXDHMMP13ADAMTS5 | |
| SCHEMBL21538213 | 0.83 | ADAMTS5 (0.77) | IDH1GSK3BMMP13ADAMTS5CNR1 | |
| SCHEMBL7972192 | 0.83 | ADAMTS5 (0.77) | IDH1GSK3BMMP13ADAMTS5CNR1 | |
| SCHEMBL20976496 | 0.83 | ADAMTS5 (0.77) | IDH1GSK3BXDHMMP13ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240071588-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20170325708-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| US-9434979-B2 | Methods and compositions for cell-proliferation-related disorders | SERVIER PHARMACEUTICALS LLC | 2016-09-06 | — | — | US | disclosed |
| US-20150240286-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC (US) | 2015-08-27 | — | — | US | disclosed |
| US-20140187435-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC (US) | 2014-07-03 | — | — | US | disclosed |
| US-20130288284-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2013-10-31 | — | — | US | disclosed |
| US-20130183281-A1 | METHODS AND COMPOSITONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2013-07-18 | — | — | US | disclosed |
| US-20120121515-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2012-05-17 | — | — | US | disclosed |
| WO-2011050210-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2010105243-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170325708-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | IDH1 300/4885GSK3B 3263/4885XDH 1989/4885 |
| US-20120121515-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | IDH1 300/4885GSK3B 3263/4885XDH 1989/4885 |
| US-20240071588-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | IDH1 300/4885GSK3B 3263/4885XDH 1989/4885 |
| US-20130183281-A1 | METHODS AND COMPOSITONS FOR CELL-PROLIFERATION-RELATED DISORDERS | IDH2, IDH1, MKI67 | IDH1 2/4885GSK3B 1267/4885XDH 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.